Sign in
Taking peopleNo phase

Multicentric Clinical Investigation to Assess Safety and Performance of Lux HighAdd IOL

Key facts

Who runs it
Cutting Edge SAS
Where
France3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
57 people, planned
Started
19 Dec 2024
Expected to end
Dec 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • LuxHighAdd IOL
  • LuxGood IOL
Record updated
26 May 2026

Who can take part

Age
50 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Subject aged 50 or over on the day of inclusion, presenting a bilateral cataract, qualified for bilateral implantation
  • No ocular comorbidity possibly affecting the study results
  • Fit within the available IOL diopter range
  • Have had no previous refractive surgery
  • Regular corneal astigmatism ≤1.0 dioptres
  • Clear intraocular media other than cataract
  • Availability, willingness and sufficient cognitive awareness to comply with examination procedures
  • Ability to attend all study follow-ups
  • Signed informed consent

Who cannot take part

  • Subjects who may be reasonably expected to require a secondary surgical intervention at any time during the investigation (other than YAG capsulotomy)
  • History of ocular trauma or any prior ocular surgery including refractive procedures
  • Systemic or ocular medication that could modify pupil dynamics
  • Expected complicated surgery or complicated surgery
  • Concurrent participation in another drug or device investigation
  • Ocular surface disease potentially affecting study results
  • Pre-existing ocular pathology or history of pathology potentially affecting the study results
  • Acute or chronic disease or illness that would increase risk or confound study results
  • Axial lengths and keratometry such as the IOL spherical power is not in the range of 16 to 26 D
  • Instability of keratometry or biometry measurements
  • Traumatic cataract
  • Amblyopia
  • Capsular or zonular abnormalities that may affect postoperative centration or tilt of the lens
  • Pupil abnormalities

This trial is currently available in France.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The study purpose is to demonstrate safety and performance of bilateral implantation of LuxHighAdd intraocular lens compared with the LuxGood Monofocal lens.

The 2 groups in the trial

  • LuxHighAddTreatment being tested

    The experimental group will recieve the LuxHighAdd intraocular lens bilaterally.

    Treatment: LuxHighAdd IOL

  • LuxGood groupExisting treatment, for comparison

    The control group will recieve the LuxGood intraocular lens bilaterally.

    Treatment: LuxGood IOL

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Multicentric Clinical Investigation to Determine Safety and Efficacy of a Hydrophobic Acrylic Multifocal Intraocular Lens
Record updated
26 May 2026